Table 1 Overview of composite lymphomas and leukemias.

Case	Lymphoma/leukemia	Age at diagnosis (years)	Gender	Concurrent or sequential	Tissue	Markers of tumor cells
1	HL and CLL	70	Male	Concurrent^a	Lymph node (HL and CLL)	HRS cells: CD30⁺, CD20⁻, CD3⁻, PAX5⁺, EBV⁺
1	HL and CLL	70	Male	Concurrent^a	Lymph node (HL and CLL)	CLL cells: CD20⁺, CD5⁺, CD23⁺, CD30⁻
2	HL and SMZL	67 (SMZL),	Male	Sequential	Lymph node (HL), spleen (SMZL)	HRS cells: CD30⁺, CD15⁻, PAX5⁺, CD20⁻, EBV^-.
2	HL and SMZL	70 (HL)	Male	Sequential	Lymph node (HL), spleen (SMZL)	SMZL cells: CD20⁺, CD5⁻, CD23⁻, CCND1⁻
3	HL and MCL	85	Female	Concurrent	Lymph node (HL and MCL)	HRS cells: CD30⁺, CD19⁻, CD20⁻, PAX5^weak, CD5⁻, CD45⁻, CCND1⁻, EBV⁻, CCND1::IGH translocation
3	HL and MCL	85	Female	Concurrent	Lymph node (HL and MCL)	MCL cells: CD45⁺, CD19⁺, CD20⁺, CD5^-, CCND1⁺, SOX11⁻, CD30⁻, CCND1::IGH translocation
4	HL and FL	61 (FL),	Female	Sequential	Lymph node (HL and FL)	HRS cells: CD30⁺, CD15^+/−, CD20⁻, EBV⁻
4	HL and FL	64 (HL)	Female	Sequential	Lymph node (HL and FL)	FL cells: CD20⁺, BCL6⁺, CCND1⁻, BCL2^+/−, CD10^+/−
5	CLL and T-PLL	77	Female	Concurrent^b	PBL	CLL cells: CD19⁺, CD5⁺, CD23⁺, Igκ⁺
5	CLL and T-PLL	77	Female	Concurrent^b	PBL	T-PLL cells: CD3⁺, CD4⁺, CD5⁺, CD8⁻
6	PCL and ALCL	73	Female	Concurrent^c	PBL	PCL cells: CD38⁺, CD138⁺, cyIgλ⁺
6	PCL and ALCL	73	Female	Concurrent^c	PBL	ALCL cells: CD3⁺, CD4⁺, CD30⁺, CD52⁺, ALK⁻

^aFirst CLL diagnosis 2 years earlier.
^bFirst, the CLL was diagnosed, and four months later both leukemias concurrently.
^cPCL first diagnosed two years earlier.

Quick links

Search